Synthetic oligonucleotides as therapeutics: The coming of age
- 1 January 2000
- book chapter
- review article
- Published by Elsevier BV in Biotechnology Annual Review
- Vol. 5, 155-196
- https://doi.org/10.1016/s1387-2656(00)05035-3
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Antisense Transforming Growth Factor-β1 in Wound HealingAntisense and Nucleic Acid Drug Development, 1997
- The Multiple Inhibitory Mechanisms of GEM 91®, agagAntisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1997
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Antisense strategies in dopamine receptor pharmacologyLife Sciences, 1997
- Renal uptake of an 18-mer phosphorothioate oligonucleotideKidney International, 1995
- Sequence-specific impairment of learning by c-jun antisense oligonucleotidesNeuroReport, 1994
- Inhibition of HIV-1 replication by a high-copy-number vector expressing antisense RNA for reverse transcriptaseGene, 1993
- Extracellular ‘communicator RNA’FEBS Letters, 1988
- Quantitative Immunocytofluorographic Analysis of CD4 Surface Antigen Expression and HIV Infection of Human Peripheral Blood Monocyte/MacrophagesAIDS Research and Human Retroviruses, 1987
- Intermediate reactions in protein biosynthesisBiochimica et Biophysica Acta, 1957